Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totaling 264 shares, a drop of 97.3% from the December 31st total of 9,733 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 27,414 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 27,414 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Matinas Biopharma Stock Down 2.2%

Shares of MTNB stock traded down $0.01 on Thursday, reaching $0.67. The company had a trading volume of 74,727 shares, compared to its average volume of 32,226. The business’s 50-day moving average is $0.71 and its 200 day moving average is $1.23. Matinas Biopharma has a one year low of $0.47 and a one year high of $3.09. The stock has a market capitalization of $4.26 million, a PE ratio of -0.19 and a beta of 1.28.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.